Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-08-26
2000-09-19
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514221, 540487, 540492, 540500, 540502, 540503, 540504, 540506, 540507, 540508, 540509, 540510, 540542, 540543, 540567, 540568, 540569, 540570, 540572, 540573, 540575, A61K 31551, C07D24308
Patent
active
06121258&
ABSTRACT:
The invention provides compounds of formula ##STR1## as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as inhibitors of metalloproteases.
Also disclosed are pharmaceutical compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.
REFERENCES:
patent: 4918105 (1990-04-01), Cartwright et al.
patent: 4996358 (1991-02-01), Handa et al.
patent: 5183900 (1993-02-01), Galardy et al.
patent: 5189178 (1993-02-01), Galardy et al.
patent: 5300674 (1994-04-01), Crimmin et al.
patent: 5310763 (1994-05-01), Campion et al.
Chapman, K.T., et al., "Inhibition of Matrix Metalloproteinases by N-Carboxyalkyl Peptides", Journal of Medicinal Chemistry, vol. 36 (1993), pp. 4293-4301.
Johnson, w.K., Roberts, N.a., and Borkakoti, N., "Collagenase Inhibitors: Their Design and Potential Therapeutic Use", Journal of Enzyme Inhibition, vol. 2 (1987), pp. 1-22.
Schwartz, M.a. Van Wart, H.E., "synthetic Inhibitors of Bacterial and Mammalian Interstitial Collagenases", Progress in Medicinal chemistry, vol. 29 (1992), p. 271.
Singh, J., et al. "Relationship Between Structure and Bioavailability in a Series of Hydroxamate Based metalloprotease Inhibitors", Bioorganic & Medicinal Chemistry Letters, vol. 5 (1995), pp. 337-342.
Tomczuk, B.E., et al., "Hydroxamate Inhibitors of the Matrix Metallo-Proteinases (MMPs) containing Novel P.sub.1 ' Heteroatom Based Modifications", bioorganic & Medicinal chemistry Letters, vol. 5 (1995), pp. 343-348.
Turbanti, L., et al., "1,2-Cyclomethylenecarboxylic Monoamide Hydroxamic Derivatives. A Novel Class of Non-amino Acid Angiotensin Converting Enzyme Inhibitors", Journal of Medicinal Chemistry, vol. 36 (1993), pp. 699-707.
Galardy et al., Inhibition of Angiogenesis by the Matrix Metalloprotease Inhibitor N-[2R-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl)]-L-tryptophan Methylamide, Cancer Research, vol. 54, No. 17, pp. 4715-4718, Sep. 1, 1994 .
Almstead Neil Gregory
Bradley Rimma Sandler
Cupps Thomas Lee
De Biswanath
McDow-Dunham Kelly Lynn
Coleman Brenda
Roof Carl J.
Shah Mukund J.
Suter David L.
The Procter & Gamble & Company
LandOfFree
1,5-heterocyclic metalloprotease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,5-heterocyclic metalloprotease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,5-heterocyclic metalloprotease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1073369